SG11201705953XA - Use of short chain fatty acids in cancer prevention - Google Patents
Use of short chain fatty acids in cancer preventionInfo
- Publication number
- SG11201705953XA SG11201705953XA SG11201705953XA SG11201705953XA SG11201705953XA SG 11201705953X A SG11201705953X A SG 11201705953XA SG 11201705953X A SG11201705953X A SG 11201705953XA SG 11201705953X A SG11201705953X A SG 11201705953XA SG 11201705953X A SG11201705953X A SG 11201705953XA
- Authority
- SG
- Singapore
- Prior art keywords
- fatty acids
- chain fatty
- short chain
- cancer prevention
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 235000021391 short chain fatty acids Nutrition 0.000 title 1
- 150000004666 short chain fatty acids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562106778P | 2015-01-23 | 2015-01-23 | |
PCT/US2016/014292 WO2016118730A1 (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201705953XA true SG11201705953XA (en) | 2017-08-30 |
Family
ID=56417737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907660Y SG10201907660YA (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
SG11201705953XA SG11201705953XA (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907660Y SG10201907660YA (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
Country Status (13)
Country | Link |
---|---|
US (4) | US10231941B2 (de) |
EP (1) | EP3247342A4 (de) |
JP (3) | JP6783247B2 (de) |
KR (1) | KR20170128247A (de) |
CN (2) | CN107405321A (de) |
AU (3) | AU2016209244A1 (de) |
CA (1) | CA2974510A1 (de) |
IL (1) | IL253581A0 (de) |
MX (1) | MX2017009532A (de) |
RU (1) | RU2017127597A (de) |
SG (2) | SG10201907660YA (de) |
WO (1) | WO2016118730A1 (de) |
ZA (1) | ZA201704977B (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CN108064132A (zh) | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | 与病症的微生物治疗和诊断有关的方法和组合物 |
SG11201704814SA (en) | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
DK3065748T3 (da) | 2014-12-23 | 2018-01-29 | 4D Pharma Res Ltd | En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
PT3360559T (pt) | 2015-06-15 | 2020-01-06 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
AU2016278067B2 (en) | 2015-06-15 | 2022-09-22 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
SG10201912326QA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB2561748B (en) | 2015-11-20 | 2019-05-08 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
KR102010207B1 (ko) | 2016-03-04 | 2019-08-12 | 4디 파마 피엘씨 | 세균 균주를 포함하는 조성물 |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
CN110891982B (zh) | 2017-04-17 | 2023-12-22 | 芝加哥大学 | 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料 |
WO2018215758A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
PL3804737T3 (pl) | 2017-06-14 | 2022-09-12 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
JP6884889B2 (ja) | 2017-06-14 | 2021-06-09 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
CA3068757A1 (en) | 2017-07-05 | 2019-01-10 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis |
WO2019025637A1 (en) * | 2017-08-04 | 2019-02-07 | Nestec S.A. | PRECONDITIONED PROBIOTIC BACTERIA IN A GOS-CONTAINING ENVIRONMENT AND USE THEREOF |
JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス, インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
CN110090230B (zh) * | 2018-01-30 | 2022-07-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
SI3743086T1 (sl) * | 2018-05-11 | 2022-05-31 | 4D Pharma Research Limited | Sestavki, ki obsegajo bakterijske seve |
US20210308196A1 (en) * | 2018-06-01 | 2021-10-07 | Evolve Biosystems, Inc. | Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires |
JP2022549896A (ja) * | 2019-09-25 | 2022-11-29 | フィリップス-ウニヴェルシテート・マールブルク | 細胞療法及び抗腫瘍療法のエンハンサーとしての短鎖脂肪酸ペンタノエート |
KR102510198B1 (ko) * | 2019-11-14 | 2023-03-15 | 가톨릭대학교 산학협력단 | 락토바실러스 속 균주 및 SCFA(Short fatty chain acid)를 포함하는 면역 질환의 예방 및 치료용 조성물 |
TWI734341B (zh) * | 2020-01-14 | 2021-07-21 | 景岳生物科技股份有限公司 | 一種副乾酪乳桿菌gmnl-346用於抗口腔癌之用途 |
AU2021231055A1 (en) * | 2020-03-05 | 2022-09-22 | Liscure Biosciences Co., Ltd. | Pharmaceutical composition comprising genus leuconostoc strain as active ingredient for prevention or treatment of cancer |
US20240009154A1 (en) * | 2020-08-04 | 2024-01-11 | Temple University-Of The Commonwealth System Of Higher Education | Methods and compositions for treating cytokine release syndrome |
US11938152B2 (en) | 2020-08-06 | 2024-03-26 | Kedar N Prasad | High-dose antioxidants in cancer treatment |
CA3198162A1 (en) * | 2020-11-12 | 2022-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Use of short chain fatty acids in cancer prevention |
WO2022177409A1 (ko) * | 2021-02-22 | 2022-08-25 | 주식회사 리스큐어바이오사이언시스 | 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
WO2023141202A1 (en) * | 2022-01-19 | 2023-07-27 | Hodgdon Ian | Short-chain fatty acids for cancer treatment |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4735967A (en) | 1985-05-28 | 1988-04-05 | Neesby Torben E | Method for desensitizing the gastrointestinal tract from food allergies |
AU645070B2 (en) | 1990-04-10 | 1994-01-06 | Nb International Technologies | Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94 |
PH31403A (en) | 1991-03-01 | 1998-10-29 | Warner Lambert Co | Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same. |
WO1995011699A1 (en) | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
JP2000072667A (ja) | 1998-08-25 | 2000-03-07 | Kurasuraa:Kk | 大腸炎治療用経口投与剤 |
US6201077B1 (en) | 1998-12-01 | 2001-03-13 | Phillips Petroleum Company | Process that produces polymers |
EP1034788A1 (de) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Milchsäure Bakterienstämme zur Verhinderung von Diarrhöe |
EP1463759B8 (de) | 2002-01-07 | 2013-07-10 | Euroscreen S.A. | Ligand für den g-protein gekoppelten rezeptor gpr43 und seine verwendungen |
NZ567758A (en) | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
EP1501489A4 (de) | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | Kombinationstherapie zur behandlung von krebs |
US8846039B2 (en) | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
WO2004024160A1 (en) | 2002-09-13 | 2004-03-25 | Virginia Commonwealth University | Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia |
US20050023179A1 (en) | 2003-07-31 | 2005-02-03 | Albritton Charles Wade | Fragile-product cage for vacuum packaging appliances |
AU2004270150C1 (en) | 2003-08-29 | 2011-07-14 | Merck Hdac Research, Llc | Combination methods of treating cancer |
WO2007016955A1 (en) | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Alcohol metabolism moderating composition |
ES2444890T3 (es) | 2006-03-31 | 2014-02-27 | Erasmus University Medical Center Rotterdam | Nueva composición para el control del crecimiento tumoral |
US20080153908A1 (en) | 2006-12-20 | 2008-06-26 | Jani Dharmendra M | Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition |
CA2711807A1 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
CN101214234B (zh) | 2008-01-10 | 2010-09-08 | 中国人民解放军第二军医大学 | α-羟基酸在制备癌瘤体内注射治疗药物中的应用 |
US9339667B2 (en) | 2009-02-18 | 2016-05-17 | Sea Qiq As | Mixture of inorganic compounds, preparations containing the mixture and use of the mixture |
ES2729765T3 (es) | 2009-06-19 | 2019-11-06 | Dupont Nutrition Biosci Aps | Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva |
US8962686B2 (en) | 2010-04-28 | 2015-02-24 | The Chinese University Of Hong Kong | Method and medication for prevention and treatment of ocular hypertension and glaucoma |
EP2389932A1 (de) | 2010-05-28 | 2011-11-30 | Lunamed AG | Zusammensetzungen zur Verwendung bei Erbkrankheiten, die 4-Phenylbuttersäure und deren Salze umfassen |
EP2616051A1 (de) | 2010-07-29 | 2013-07-24 | Cosmo Technologies Ltd. | Pharmazeutische und/oder diätetische zusammensetzungen auf basis von kurzkettigen fettsäuren |
KR101747815B1 (ko) | 2010-11-29 | 2017-06-15 | 유니버시티 푸트라 말레이지아 | 종양 세포독성제 및 그 방법 |
WO2012118535A1 (en) * | 2011-03-01 | 2012-09-07 | Quorum Innovations, Llc | Materials and methods for treating conditions associated with pathogenic biofilm |
WO2012131069A1 (en) | 2011-03-31 | 2012-10-04 | Proponent Biotech Gmbh | Short chain fatty acids and their derivatives for use in treatment immunogenic disorders |
JP6632802B2 (ja) | 2012-01-16 | 2020-01-22 | マッケンナ,エリザベス | 肝疾患及び肝障害を治療するための組成物及び方法 |
GB201215289D0 (en) | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
TWI463986B (zh) | 2012-08-29 | 2014-12-11 | Univ China Medical | 胚芽乳酸桿菌cmu995菌株之新用途 |
JP2016530239A (ja) | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
EP3033091B1 (de) * | 2013-08-16 | 2022-09-07 | Versitech Limited | Probiotische zusammensetzung und ihre verwendung zur prävention und behandlung von hepatozellulärem karzinom |
-
2016
- 2016-01-21 CN CN201680017250.3A patent/CN107405321A/zh active Pending
- 2016-01-21 CA CA2974510A patent/CA2974510A1/en active Pending
- 2016-01-21 EP EP16740745.1A patent/EP3247342A4/de active Pending
- 2016-01-21 CN CN202210967776.5A patent/CN115350171A/zh active Pending
- 2016-01-21 KR KR1020177023391A patent/KR20170128247A/ko not_active Application Discontinuation
- 2016-01-21 MX MX2017009532A patent/MX2017009532A/es unknown
- 2016-01-21 RU RU2017127597A patent/RU2017127597A/ru not_active Application Discontinuation
- 2016-01-21 US US15/545,371 patent/US10231941B2/en active Active
- 2016-01-21 AU AU2016209244A patent/AU2016209244A1/en not_active Abandoned
- 2016-01-21 JP JP2017557279A patent/JP6783247B2/ja active Active
- 2016-01-21 SG SG10201907660Y patent/SG10201907660YA/en unknown
- 2016-01-21 SG SG11201705953XA patent/SG11201705953XA/en unknown
- 2016-01-21 WO PCT/US2016/014292 patent/WO2016118730A1/en active Application Filing
-
2017
- 2017-07-19 IL IL253581A patent/IL253581A0/en active IP Right Grant
- 2017-07-21 ZA ZA2017/04977A patent/ZA201704977B/en unknown
-
2018
- 2018-02-23 US US15/903,395 patent/US10143669B2/en active Active
-
2019
- 2019-01-30 US US16/261,836 patent/US20190160031A1/en not_active Abandoned
- 2019-03-15 AU AU2019201799A patent/AU2019201799B2/en active Active
-
2020
- 2020-09-23 AU AU2020239699A patent/AU2020239699A1/en not_active Abandoned
- 2020-10-21 JP JP2020176442A patent/JP2021020929A/ja active Pending
-
2021
- 2021-07-19 US US17/379,305 patent/US11963938B2/en active Active
-
2022
- 2022-12-08 JP JP2022196339A patent/JP2023027219A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2974510A1 (en) | 2016-07-28 |
AU2019201799A1 (en) | 2019-04-04 |
ZA201704977B (en) | 2022-12-21 |
EP3247342A1 (de) | 2017-11-29 |
CN115350171A (zh) | 2022-11-18 |
US20180185307A1 (en) | 2018-07-05 |
JP2023027219A (ja) | 2023-03-01 |
AU2019201799B2 (en) | 2020-10-15 |
US20190160031A1 (en) | 2019-05-30 |
RU2017127597A3 (de) | 2019-07-17 |
SG10201907660YA (en) | 2019-10-30 |
JP2021020929A (ja) | 2021-02-18 |
AU2020239699A1 (en) | 2020-10-15 |
AU2016209244A1 (en) | 2017-08-17 |
JP2018504457A (ja) | 2018-02-15 |
MX2017009532A (es) | 2018-04-10 |
CN107405321A (zh) | 2017-11-28 |
US20180008565A1 (en) | 2018-01-11 |
US20220008369A1 (en) | 2022-01-13 |
EP3247342A4 (de) | 2018-10-10 |
IL253581A0 (en) | 2017-09-28 |
JP6783247B2 (ja) | 2020-11-11 |
US10231941B2 (en) | 2019-03-19 |
RU2017127597A (ru) | 2019-02-25 |
WO2016118730A1 (en) | 2016-07-28 |
US10143669B2 (en) | 2018-12-04 |
KR20170128247A (ko) | 2017-11-22 |
US11963938B2 (en) | 2024-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201704977B (en) | Use of short chain fatty acids in cancer prevention | |
HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
IL258955A (en) | Preparations and methods for the treatment of cancer | |
HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
ZA201607540B (en) | Compositions and methods to treating hemoglobinopathies | |
SI3200815T1 (sl) | Postopki in sestavki za zdravljenje raka | |
HRP20190888T8 (hr) | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma | |
IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
SG11201608217PA (en) | Fatty acid composition and use thereof | |
SG11201803022TA (en) | Compositions comprising fatty acids and their use | |
GB201420533D0 (en) | Use of Nanomaterials in treating cancer | |
HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
SG10202001388YA (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
GB201408297D0 (en) | Treatment of cancer | |
PL3233074T3 (pl) | Leczenie niealkoholowych stłuszczeniowych chorób wątroby | |
SI3229790T1 (sl) | Kompozicije, ki vsebujejo srednjeverižne trigliceride in ki se uporabljajo za zdravljenje epilepsije | |
GB201417456D0 (en) | Treatment of cancer | |
GB201410695D0 (en) | Uses of oligouronates in cancer treatment | |
ZA201403006B (en) | Composition for use in treatment of cancer | |
GB201419559D0 (en) | Therapeutic compositions and methods | |
GB201409362D0 (en) | Treatment of cancer | |
GB201405449D0 (en) | Treatment of cancer | |
GB201405075D0 (en) | Treatment of cancer |